Paragon Biosciences, a life science innovator that creates, invests in and builds life science companies in biopharmaceuticals, cell and gene therapy and synthetic biology utilizing artificial intelligence, today announced the acquisition of CiRC Biosciences, a cell therapy company developing treatments for serious diseases with high, unmet needs with an initial focus on the eye. CiRC Biosciences is currently advancing pre-clinical development of chemically induced retinal cells for vision restoration in Geographic Atrophy Age-Related Macular Degeneration (Dry AMD), which is the most common cause of irreversible vision loss over the age of 65, and advanced Retinitis Pigmentosa (RP), a genetic disorder that causes tunnel vision and eventual blindness.
Read the full article: Paragon Biosciences Adds CiRC Biosciences to Expand Cell and Gene Therapy Platform //
Source: https://www.prnewswire.com/news-releases/paragon-biosciences-adds-circ-biosciences-to-expand-cell-and-gene-therapy-platform-301219552.html